Crofelemer

Drug Profile

Crofelemer

Alternative Names: CRO-HIV; CRO-IBS; CRO-ID; CRO-PED; Fulyzaq; Mytesi; Provir; SP 303; TRN-002; Virend

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shaman Pharmaceuticals
  • Developer Napo Pharmaceuticals; Shaman Pharmaceuticals
  • Class Antidiarrhoeals; Biopolymers; Chromans; Flavonoids; Phytotherapies
  • Mechanism of Action Chloride channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diarrhoea
  • Phase II Irritable bowel syndrome
  • Preclinical Short bowel syndrome
  • Discontinued Herpes simplex virus infections; Influenza virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Diarrhoea(In children) in USA (PO, Tablet)
  • 18 Oct 2017 Pooled adverse events data from clinical trials released by Napo Pharmaceuticals
  • 25 Sep 2017 Napo reacquires rights to crofelemer from Glenmark in 141 countries including India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top